Combating drug-resistant fungal infections

There are millions of fungal species, and a few hundred of them can make people very sick.¹

Antifungal drugs treat fungal infections by killing or stopping the growth of dangerous fungi in the body. However, fungi, like bacteria, can develop antibiotic resistance, when germs develop the ability to defeat the drugs designed to kill them.²

Some types of fungi, like Candida auris, can be resistant to all three available antifungal drugs types. Resistance is especially concerning for patients with invasive fungal infections, frequently causing morbidity and mortality, especially in transplant recipients.²

60P is currently exploring the potential of tafenoquine (TAF), approved by regulators as an antimalarial, to combat other pathogens.^3*

*ARAKODA has not been reviewed or approved by the U.S. Food and Drug Administration for the treatment or prevention of COVID-19, babesiosis, or fungal diseases.

References: 1. Centers for Disease Control and Prevention. Fungal Diseases. Types of Fungal Diseases. Page last reviewed: May 6, 2019. https://www.cdc.gov/fungal/diseases/index.html. Accessed August 15, 2022. 2. Garcia-Bustos V, Cabanero-Navalon MD, Ruiz-Sari A, et al. What do we know about Candida auris? Microorganisms. 2021;9:1–20. 3. Dow GS, Smith BL. Tafenoquine exhibits broad spectrum antifungal activity at clinically relevant concentrations in vitro and decreases lung fungal burden in an invasive pulmonary model of Rhizopus in vivo. New Microbe New Infect. 2022; 45: 100964. doi:10.1016/j.nmni.2022.100964.